Christopher Darr

German Cancer Research Center — Germany

Medicine · Health Sciences

16h-index1.2kcitations156works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(35), Bladder and Urothelial Cancer Treatments(35), Prostate Cancer Treatment and Research(33), Prostate Cancer Diagnosis and Treatment(29), Cancer Immunotherapy and Biomarkers(21)

Publications156 total

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study
Urologic Oncology Seminars and Original Investigations·2026
Predictors of Biochemical Recurrence in Patients with Positive Surgical Margin After Radical Prostatectomy
Urology Research and Practice·2025Open Access
Prostate-specific Membrane Antigen Positron Emission Tomography Versus Conventional Imaging for Preoperative Staging High-risk Prostate Cancer Patients Undergoing Surgery for cN0M0 Disease: An European Association of Urology—Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study
European Urology Oncology·2025
Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
2025Open Access
Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
2025Open Access
Supplementary Data TS2 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
2025Open Access
Molekulare Therapie in der Therapiesequenz des metastasierten Blasenkarzinoms
Die Onkologie·2025
Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis
European Urology Open Science·2025Open Access
Spatial atlasing of N-glycosylation in healthy control and clear cell renal cell carcinoma tissues linked with immune checkpoint inhibition response by MALDI mass spectrometry imaging
Analytica Chimica Acta·2025Open Access
Immune-related hepatic adverse events in renal cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective study
BJC Reports·2025Open Access
Korrelation von Gesamtüberleben und RECIST-definiertem Ansprechen bei Patienten mit soliden Tumoren und Therapie mit Immuncheckpoint-Inhibitoren – Gepoolte Analyse der RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC und TITAN-TCC Studien der AiO Studiengruppe
Zeitschrift für Gastroenterologie·2025Open Access
2597MO [68Ga]Ga-DPI-4452 PET/CT for staging of patients with clear cell renal cell carcinoma
Annals of Oncology·2025
Transcriptomic Profiling of the Tumor Immune Microenvironment Reveals Prognostic Markers in mCRPC Patients Treated with LuPSMA Therapy
Theranostics·2025· 1 citedOpen Access
Neue Immuncheckpointinhibitoren und Kombinationen
Die Onkologie·2025
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project
European Urology Open Science·2025Open Access
481P The predictive role of neutrophil-to-lymphocyte ratio in patients with solid cancers treated with immune checkpoint inhibitors: A pooled analysis of seven clinical trials of the German AIO study group
Annals of Oncology·2025Open Access
Treating the untended: Real-world insights into enfortumab vedotin plus pembrolizumab for frail metastatic urothelial carcinoma patients excluded or underrepresented in clinical trials (GUARDIANS).
Journal of Clinical Oncology·2025
Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis
ESMO Real World Data and Digital Oncology·2025Open Access
IP05-27 TRANSCRIPTOMIC PROFILING OF THE TUMOR IMMUNE MICROENVIRONMENT REVEALS PROGNOSTIC MARKERS IN MCRPC PATIENTS TREATED WITH LUPSMA THERAPY
The Journal of Urology·2025
PD30-07 CONVENTIONAL PSMA-PET/CT, MPMRI AND INTRAOPERATIVE EX VIVO SPECIMENPET/CT FOR THE ASSESSMENT OF ACCURACY OF EXTRAPROSTATIC EXTENSION – POTENTIAL OF MOLECULAR-GUIDED NERVE SPARING
The Journal of Urology·2025
page 1 of 8Next →

Frequent Co-authors

Boris Hadaschik(33), Claudia Kesch(19), Ulrich Krafft(19), Stephan Tschirdewahn(15), Henning Reis(15), Jan Philipp Radtke(14), Wolfgang P. Fendler(12), Viktor Grünwald(11), Ken Herrmann(11), Tibor Szarvas(10), Pedro Fragoso Costa(10), Lukas Püllen(9), Katrin Schlack(6), Jochen Heß(6), Nina N. Harke(6), Philipp Ivanyi(5), Péter Nyírády(5), Andrej Panic(5), Niklas Klümper(4), Friedemann Zengerling(4)